Wockhardt Ltd
WOCKPHARMABSE 532300PharmaceuticalsMkt cap ₹33,903 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹929 Cr
YoY +25.9%QoQ -3.7%
Net profit · Q1 FY27
₹107 Cr
YoY —QoQ -34.8%
Net margin · Q1 FY27
11.5%
+26.1 pts vs Q1 FY26
Net profit · FY26
₹199 Cr
YoY —
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 929 | 965 | 888 | 782 | 738 | +25.9% |
| Other income | 31.00 | 45.00 | 25.00 | 21.00 | 20.00 | +55.0% |
| Total income | 960 | 1,010 | 913 | 803 | 758 | +26.6% |
| Profit before tax | 116 | 189 | 67.00 | 91.00 | 0.00 | — |
| Tax | 9.00 | 25.00 | 6.00 | 9.00 | -1.00 | — |
| Net profit | 107 | 164 | 61.00 | 82.00 | -108 | — |
| Net margin | 11.5% | 17.0% | 6.9% | 10.5% | -14.6% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 3,373 | 3,012 | 2,798 | 2,651 | 3,230 | +12.0% |
| Other income | 111 | 62.00 | 83.00 | 122 | 20.00 | +79.0% |
| Total income | 3,484 | 3,074 | 2,881 | 2,773 | 3,250 | +13.3% |
| Profit before tax | 238 | 0.00 | -420 | -624 | -411 | — |
| Tax | 39.00 | 41.00 | 52.00 | -3.00 | -132 | -4.9% |
| Net profit | 199 | -57.00 | -472 | -621 | -279 | — |
| Net margin | 5.9% | -1.9% | -16.9% | -23.4% | -8.6% |
BIC's take
We haven't covered Wockhardt Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 6:30 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.